This may in part reflect the biological characteristics of tumors arising in an immune privileged site. Lymphomas arising under the selective pressure of immune surveillance may develop an immune escape phenotype. 16 Common to both PTL and primary CNS lymphoma (PCNSL) are high levels of IgVH somatic hypermutation 17 and loss of HLA expression resulting from gene deletions 18, 19 which may assist evasion of the host anti-tumor response. In addition, a nascent PTL clone may benefit from developing in an immune privileged site behind the blood-testis barrier, which has several components designed to shield developing gametocytes. These include: 1) a mechanical barrier formed by the tight junction between Sertoli and endothelial cells preventing the passage of large/hydrophilic molecules, 20 2) an efflux pump (P-glycoprotein, MRP1) for smaller/lipophilic molecules, 3) an immunological barrier formed by Sertoli cells hindering passage of antibodies 21 and 4) local production of anti-inflammatory cytokines. 22 Menter et al studied 45 cases of PTL using immunohistochemistry (IHC) and FISH, finding low levels of p53 expression but high levels of phosphorylated (p)STAT3, overexpression of pCXCR4, and upregulation of the NF-κb pathway. 23 Although few patients had clinical outcome data available, expression of both CXCR4 and pCXCR4 was predictive of inferior progression-free survival (PFS) (P=0.007). Little is known about the role of CXCR4 expression in lymphoma, though the chemokine receptor has myriad biological functions including trafficking of lymphocytes to sites of inflammation, hematopoetic cell homing, trafficking of tumor cells to target organs, proliferation and directed migration of neuronal cells, and infiltration of activated monocytes to areas of ischemic injury. 24 Preclinical models have shown directed metastasis is mediated by CXCR4 activation and migration toward CXCR12 expressing target organs. 24 Thus overexpression of CXCR4 may predispose PTL toward extranodal relapse. Recommended staging is as for other forms of aggressive NHL (PET-CT, bone marrow biopsy) with the addition of specific CNS staging with lumbar puncture for CSF analysis by cytology and flow cytometry (as there is evidence to support improved sensitivity 29 ) and brain MRI. We recommend thorough examination of the skin as cutaneous "DLBCL, leg type" and testicular DLBCL have been concurrently reported 30 and the skin is a potential site of extranodal recurrence. HIV serology should be performed. As with other forms of NHL, the Ann Arbor system is used for staging, although this was not specifically designed for extranodal lymphomas.
Patients with isolated bilateral involvement of the testes have similar prognosis to stage I/II disease, 31 and therefore we agree with existing recommendations that such cases be considered stage I. 32 In the largest series, 60-79% of patients were stage I/II at presentation 3, 7, 33, 34 although from a pragmatic perspective, patients with stage III/IV "primary" testicular lymphoma can be considered identical to systemic nodal DLBCL with secondary testicular involvement. Making distinctions between the two entities is difficult and somewhat arbitrary, as usually it cannot be determined in 
Cell of origin studies and chromosomal translocations
For personal use only. on August 16, 2017. by guest www.bloodjournal.org From In PTL of DLBCL histology, cell of origin determined either by IHC-based algorithms 48 and/or DNA microarray is activated B-cell (ABC)-type in 60-96% of cases. 4, 37, [49] [50] [51] The variation in frequency is dependent on both the proportion of patients with advanced stage disease (where it is difficult to distinguish PTL from nodal DLBCL with testicular metastases) and the IHC algorithm employed. 48 The true proportion of cases which are ABC-type is likely to be at the higher end of the published estimates, as although 6-36% of cases are CD10+ in published series 37, 49, 51 are classified as GCB-type by the Hans algorithm 48 , many also express the B-cell activation marker MUM1. Some scoring systems consider such cases to be ambiguous, fitting neither ABC nor GCB-subtype. 52 Booman et al determined cell of origin using both IHC and gene expression profiling. 49 By IHC, 14 (64%) were clearly ABC-type (CD10-Bcl6 +/-MUM1+) however 8 (36%) were classified as 'ambiguous' (CD10+ Bcl6+ MUM1+), and 7/8 (88%) of these ambiguous cases were re-classified as ABC-type by gene expression analysis. This predominance of ABC-type may partially account for the historically poor outcomes from PTL. 53 Recent data in nodal DLBCL suggest that the adverse outcome conferred by ABC-subtype may be attributable to chronic active Bcell receptor signalling, constitutive NF-κB and PI3K activation. 54 Interestingly, a large international consortium found that co-expression of MYC and Bcl-2 protein contributed to the inferior survival of ABC-type nodal DLBCL. 55 However, the limited data available suggests the frequency of either proteomic or cytogenetic "double hit" with MYC and Bcl-2 in PTL is low. Bernasconi et al performed cytogenetic analyses using split signal FISH probes in 16 patients with PTL, finding 3 cases (19%) bearing MYC translocations. 56 Menter et al found only 5/38 (13%) PTL cases expressed cmyc protein, but all five also expressed Bcl-2 protein. 23 Finally, the dependence of ABC-type DLBCL on MYD88, an adaptor protein which acts through toll and IL-1 receptor, was recently described. 57 Kraan et al found mutations in MYD88 in >70% of PTL and PCNSL, but <20% of patients with nodal DLBCL, providing further evidence for differences in pathophysiology. 58 For personal use only. with limited stage disease the IPI is typically <2 and therefore has limited prognostic utility. 59 The adverse prognostic markers for PFS are summarised in Table 1 ; those for OS are similar with one study also identifying infiltration of adjacent tissues. 60 The impact of non-DLBCL histology is difficult to determine because of the rarity of such cases. A Dutch series found evidence of transformed extranodal marginal zone lymphoma was associated with smaller tumor size, less frequently elevated LDH, absence of B-symptoms, more frequent stage IE disease and lower IPI than "pure" DLBCL and non-significant trend toward improved survival. 40 A particular characteristic of PTL is the temporal pattern of continuing relapses, even >15 years after initial treatment which frequently involves sanctuary sites such as the contralateral testis and CNS. 3 Often relapses occur at multiple extranodal sites including lung, soft tissue, adrenals, liver and bone marrow. 3, 5, 11, 12 The crude incidence of CNS involvement in PTL has been reported in smaller series as up to 44%, although estimates vary widely and use of CNS-directed prophylaxis was typically non-uniform. 3, 5, 11, 33, 61 The best estimate of risk in the pre-rituximab era is the large, retrospective International Extranodal Lymphoma Study Group (IELSG) series of 381 patients with PTL. 12 The 5-and 10-year actuarial risks of 19% and 34% are substantially greater than nodal DLBCL. 62 As is the case in nodal DLBCL 63 , CNS parenchymal relapse is more frequent than leptomeningeal; in the IELSG series 64% of CNS relapses involved brain parenchyma and 61% were isolated to the CNS, consistent with other series. 12 For personal use only. Historically the outcome of PTL has been inferior to nodal DLBCL with no plateau in PFS and OS curves in retrospective studies (Table 2) . 4, 5, 9, 11, 12, 33, 64 As previously outlined, orchiectomy alone is indicated both for diagnostic and therapeutic purposes. However, outcomes of patients treated with orchiectomy and/or radiation alone are poor. 7,65 Many chemotherapy strategies have been used; the rarity of the tumor has prevented the conduct of prospective randomised comparisons between chemotherapy strategies. Thus the available data are drawn from either nonrandomised phase II studies or retrospective series.
The outcome of patients with PTL has gradually been improving. A retrospective MD Anderson Cancer Centre (MDACC) series showed incremental improvements in PFS and OS over time with refinement of treatment strategy (Figure 1 ). 11 This trend is mirrored by the SEER registry in which analysis by 'treatment era' (defined by 5-year intervals) showed incremental improvements in OS, with the median OS 1.8 years for patients diagnosed in 1980-1985 but median not yet reached for those diagnosed 20 years later (5-year disease-specific survival 62.4%). 7 Based on nodal DLBCL, CHOP at 3-weekly intervals was the most widely used regimen for PTL prior to the introduction of rituximab, achieving 5-year OS of 30-52%. 11, 66 Attempts to improve on this with the addition of bleomycin, 10,67 increasing dose density 10 or use of more intensive strategies such as Hyper-CVAD 64 
The apparent lack of impact of rituximab on CNS relapse risk in the BCCA series is unsurprising, given that CSF levels of rituximab are only 0.1% that of serum levels 69 and a recent meta-analysis suggested only minor reduction in CNS relapse in nodal DLBCL. 62 In an attempt to ameliorate the high risk of CNS relapse, IT chemotherapy has been used in many retrospective series. [3] [4] [5] 11 patients. 71 In all three studies, the crude incidence of CNS relapse was significantly less than historic controls. Given that many relapses are parenchymal rather than leptomeningeal and the penetration into brain parenchyma and distribution around the neuroaxis of methotrexate injected by lumbar puncture is limited 72 , there is conceptual appeal to the use of high-dose systemic methotrexate for CNS prophylaxis, as it achieves higher drug levels in brain parenchyma. 73 All patients received radiotherapy (RT) to inguinal, iliac, and para-aortic lymph nodes, whole brain RT and IT prophylaxis. 70 With a median follow up of 73.5 months, the DFS and OS were 70% and 65% respectively, with one CNS relapse (6%). Finally, the IELSG-10 study was a phase-II multicentre study which evaluated RCHOP delivered at three weekly intervals followed by locoregional irradiation. 59 CNS prophylaxis was IT methotrexate during the first two chemotherapy cycles. Fiftythree patients with stage I/II DLBCL type PTL were included (patients with bilateral testicular involvement were considered stage I); 98% achieved CR and after median follow up of 65 months, the 5-year PFS and OS were 74% and 85%, respectively. 
Testicular irradiation
Patients treated by orchiectomy and anthracycline-based chemotherapy have an appreciable risk of relapse in the contralateral testis. 1, 3, 9 In the IELSG series, testicular relapse was a component of 43/195 (45%) treatment failures, with 15-year actuarial incidence of contralateral testicular relapse 42% in the absence of scrotal irradiation. 12 Prophylactic scrotal radiation was associated with significant reduction in the incidence of testicular relapse (P=0.011) and improvement in both 5-year PFS (70 v 36%, P=0.00001) and OS (66 v 38%, P=0.00001). 12 Other studies have also suggested the addition of adjuvant RT improves survival, although it is uncertain to what extent this reflects patient selection for adjuvant irradiation. 7, 78 In the IELSG-10 study, adjuvant testicular radiation (median 30, range 24-40 Gy) was used routinely with no testicular relapses observed. 59 RT should thus be considered mandatory in stage I-II disease. Adjuvant scrotal radiation may have more value in limited stage disease, as in the IELSG series, testicular relapse occurred in 28% of treatment failures for stage-I and was sole initial site of failure in 10%, whereas for patients with initial stage III-IV, testicular relapse occurred in 16% of failures but was sole site of failure in only 2%. Nonetheless given the relatively low morbidity of this treatment, it should be considered standard care for all patients having potentially curative chemotherapy. Despite this, the SEER data showed only 30-40% of patients received RT, without apparent improvement over time. 7
Nodal Irradiation
In Stage I PTL there is no role for adjuvant irradiation to uninvolved para-aortic or pelvic nodes. In stage II PTL, the benefit of RT to involved nodes in patients treated with RCHOP is uncertain. For example, in the IELSG-10 study, of 13 stage II patients, nine received nodal RT and the single relapse occurred in one of these patients, within the radiotherapy field. 59 The four patients not treated with RT were all For personal use only. on August 16, 2017. by guest www.bloodjournal.org From in remission at the time of reporting -however the small number and nonrandomized allocation of RT means that this question remains open. There are limited data to suggest benefit of regional nodal irradiation in stage III/IV disease, and as such this is not recommended.
Toxicity
Testicular irradiation causes acute cutaneous toxicity, which may last several weeks.
The major long-term toxicities of scrotal irradiation are dose dependent and include infertility and hypogonadism. 79 The acute toxicities of abdominal and pelvic irradiation include lethargy, nausea, disturbance of bowel function and cytopenias whilst late toxicity primary consists of increased risk of second primary malignancies. It is difficult to make robust evidence based recommendations for the optimal approach for patients with relapsed PTL. Four of 18 (22%) patients with relapsed lymphoma in the MDACC series underwent autologous stem cell transplantation, but their outcomes were not reported. 11 Interestingly, of the nine patients with relapsed lymphoma in the IELSG-10 study, four (44%) remained alive in second remission after unspecified salvage therapy, 59 perhaps suggesting that prevention of CNS relapse may result in greater potential to salvage patients in the future. Table 3 . Prospective studies in primary testicular lymphoma. Abbreviations: DLBCL = diffuse large B-cell lymphoma, RCEOP* = rituximab, cyclophosphamide (1500mg/m 2 ), epirubicin (120mg/m 2 ), vincristine, prednisolone; CEOP-B = cyclophosphamide, epirubicin, vincristine, prednisolone, bleomycin; VCAP = vindesine, doxorubicin, cyclophosphamide, prednisolone; VECP-bleo = vindesine, epirubicin, cyclophosphamide, prednisolone, bleomycin; EFS = event-free survival; PFS= progression free survival, OS = overall survival; MTX= methotrexate; RT: radiotherapy. For personal use only. on August 16, 2017. by guest www.bloodjournal.org From Figure 2 . Time to CNS recurrence in the IELSG retrospective study, demonstrating ongoing risk of late CNS relapses. With permission from Zucca et al. 12 For personal use only. on August 16, 2017. by guest www.bloodjournal.org From
